Drug interactions
Erdafitinib + Pazopanib
Severity: Moderate
Erdafitinib and Pazopanib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib inhibits P-glycoprotein, and pazopanib is a P-gp substrate, so pazopanib exposure may increase. The clinical effect is uncertain, but higher levels could worsen hepatotoxicity and hypertension.
What this interaction means in plain words
Erdafitinib and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Erdafitinib belongs to Oncology; Pazopanib belongs to Oncology.
Why it happens
Inhibition of P-gp efflux of pazopanib, which may increase its absorption and exposure.
What to do
Monitor liver tests and blood pressure during coadministration. Reduce pazopanib if adverse effects occur.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Pazopanib
- Adagrasib + Pazopanib Major
- Amiodarone + Pazopanib Major
- Amisulpride + Pazopanib Major
- Amobarbital + Pazopanib Major
- Anagrelide + Pazopanib Major
- Apalutamide + Pazopanib Major
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Pazopanib?
MediHelp rates the interaction as moderate. Erdafitinib and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib inhibits P-glycoprotein, and pazopanib is a P-gp substrate, so pazopanib exposure may increase. The clinical effect is uncertain, but higher levels could worsen hepatotoxicity and hypertension.
How serious is the interaction between Erdafitinib and Pazopanib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor liver tests and blood pressure during coadministration. Reduce pazopanib if adverse effects occur.
What other medicines interact with Pazopanib?
MediHelp also lists interactions of Pazopanib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Pazopanib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
